Focal Adhesion Kinase signaling pathway and its functions have been involved in the development and aggressiveness of tumor malignancy, it then presents a promising cancer therapeutic target. Several reversible FAK inhibitors have been developed and are being conducted in clinical trials. On the other hand, irreversible covalent inhibitors would bring many desirable pharmacological features including high potency and increased duration of action. Herein we report the structureguided development of the first highly potent and irreversible inhibitor of the FAK kinase. This inhibitor showed a very potent decrease of autophosphorylation of FAK in squamous cell carcinoma. A cocrystal structure of the FAK kinase domain in complex with this compound revealed the inhibitor binding mode within the ATP binding site and confirmed the covalent linkage between the targeted Cys427 of the protein and the inhibitor.
inhibitors are interesting since the decrease of tumor growth and metastasis development was observed in some preclinical models and in cancer patients, even if some adverse events have been revealed. 7 In order to enhance the efficacy of antiFAK cancer treatments the trials are conducted either individually or in combination. Recent advances in the evaluation of FAK inhibitors in preclinical and clinical models are very promising. [7] [8] Furthermore, FAK has recently been shown to be localized in the nucleus and could promote survival and cell proliferation by interacting directly with p53. 9 FAK inhibition could also trigger immune mediated tumor regression through the control of regulatory Tcell (Treg) in the tumor environment. 10 The development of covalent irreversible inhibitors to target kinases have recently garnered significant interest. [11] [12] From a therapeutic point of view, the main advantages of irreversible inhibitors are i) an increase of the target residence time to obtain durable inhibition without maintaining continuous drug exposure; ii) a better ability to avoid drug resistance by reducing the development of resistance mutations. 13 Although there is only very few of irreversible tyrosine kinase inhibitors used as therapeutic agents in the fields of oncology nowadays, the number of these new inhibitors is steadily increasing to enter clinical trials.
RESULTS AND DISCUSSION
Design of Irreversible Covalent Inhibitors. In order to assess the feasibility of designing irreversible inhibitors of FAK, our strategy entailed identifying a suitable cysteine residue within or next to the ATP binding pocket. This approach would be amenable by using a kinomewide sequence analysis in connection with 3D structure of the ATP site. In particular, we noticed that FAK contains a cysteine residue in the Glycinerich loop region closer to the ATP site, a feature which is not observed in most of other human kinases ( Figure   1A ). The distance between Cys427 and a reversible inhibitor, such as TAE226 (PDB ID: 2JKK) 14 or PHM16 (PDB ID: 4BRX) 15 in the ATP binding site is less than 10 Å ( Figure 1B ).
Based on the twostep process for kinase inhibition, we designed our inhibitors, which first bind reversibly to the enzyme, forming a noncovalent complex, and then form a covalent binding with the residue Cys427 of the enzyme to provide an irreversible complex (Figure S1, equation 1). Pyrimidine derivatives, especially 2,4dianilinopyrimidine derivatives, are one of the important scaffolds found in many compounds described by pharmaceutical companies and academic laboratories. 6, [16] [17] [18] These pyrimidinecontaining inhibitors efficiently target the FAK scaffolding function and suppress tumor growth through inhibition of Akt signaling or activation of p53 signaling and its downstream targets. 10 Our design strategy required the synthesis of 2,4pyrimidine derivatives as a scaffold to maintain affinity similar to reversible inhibitors (compound 2, Figure 1C ), and inclusion of a linker with Michael acceptor which could react with the nucleophilic Cys427 residue. A number of diverse linkers were evaluated, we quickly focused upon two linkers, a squarate (3,4bisaminocyclobutane1,2dione) (5 and 6) and a 1,2,3triazole (7 and 8) motif which are able to sustain a good orientation to target Cys427 in the Glycinerich loop region of the FAK kinase. Concerning the electrophile motif, an acrylate group was chosen to maintain reactivity (5, 7 and 8 in Figure 1C ). 
Biochemical Characterization of FAK Inhibitors.
To establish whether our rationally designed targeted covalent inhibitors 5, 7 and 8 could form irreversible complexes, their inhibitory potency were first assessed using an ADP-Glo TM kinase assay. One previously reported inhibitor of FAK, TAE226, was used as a control. In this assay, TAE226 showed IC50 value of 5.8 nM against the kinase activity of FAK (Table 1) , which was similar to previously reported data. 19 As expected, our selected 2,4-dianilinopyrimidine scaffold (compound 2) showed a potent inhibitory activity to FAK (IC50 = 26 nM), as shown in Table 1 Interestingly, for 5, it is observed that two hydrogen bonds are formed between the side chain nitrogen of Arg426 and the carbonyl of the squarate, and the CO of Ile428 forms a hydrogen bond with the NH of the squaramide attached to the benzylamino moiety ( Figure 5 ).
On the contrary, 1,2,3-triazole group can not make this type of the interaction ( Figure 5 ), supporting that the binding of the squarate group to the FAK active site is crucial to guide the electrophilic group of 5 for reaction with the nucleophilic thiol group of Cys427 ( Figure 4A ). Furthermore, only the cocrystal structure with 5 revealed a strong and continuous electron density between C427 and the electrophilic carbon in 5 ( Figure 4D ) and thus clearly confirmed a covalent bond formation. skin carcinogenesis assay as previously described. 20 In a previous study, we have demonstrated that PF-562,271, a reversible inhibitor of FAK kinase was able to block the 3D proliferation of the SCC cells, cause squamous cell carcinoma regression and inhibit tumor growth in vivo. 21 The anti-proliferation of the irreversible inhibitor 5 against SCC cells was first assessed using cell nuclei counts, and VS-4718, a highly potent reversible inhibitor of FAK which is under clinical development, 22 was used as a control. Treatment of SCC FAK-WT cells with 5 resulted in a dose-dependent inhibition of proliferation with similar ED50
(1.73 ± 0.1 M) as that of VS-4718 (1.49 ± 0.2 M) ( Figure S3 ).
Covalent inhibition of FAK by compound 5 in SCC cells. We tested the inhibition of
FAK autophosphorylation in SCC cell line with the irreversible inhibitor 5. As shown in Figure 6a , compound 5 blocked Tyr397 phosphorylation in a dose-dependent manner and FAK autophosphorylation was significantly inhibited at low concentrations in these cancer cell lines, which is comparable to VS-4718. This is also consistent with its inhibitory activity against the FAK kinase, suggesting that this compound is able to effectively inhibit cellular FAK autophosphorylation and phosphorylation of kinase targets at low concentrations. Then, we examined the reversibility of the autophosphorylation of Tyr397 of FAK by performing washout experiments. Upon washout, VS-4718 lost its inhibition capacity against FAK, which is coherent with its reversible property. In contrast, 5 retained potent inhibition of FAK after washing out the inhibitor, and demonstrated covalent binding (Figure 6d ). compound showed only 21% inhibition on the IR (insulin receptor) kinase even at the high concentration of 1 μM. This is in contrast to TAE226, which exhibited high potency towards IR (IC50 = 26 nM). 19 Even if TAE226 has displayed a potent antitumor effect both in vitro and in vivo in a large variety of cancers such as brain tumors, 23 esophageal cancer, 24 breast cancer, 25 ovarian cancer, 26 and gastrointestinal stroma tumor, 27 TAE226 never entered in clinic studies, because this compound inhibited the insulin receptor with a high potency and showed important side effects in animal studies. 19 
CONCLUSIONS
In summary, we described the first irreversible sub-nanomolar inhibitor of FAK Crystallization and Structure Determination. The kinase domain of the avian FAK protein (FAK411-686) was expressed and purified following a previously described assay. 28 The inhibitor-FAK complex was formed by incubation of the compound (final concentration 10 mM) with the protein (8 mg/mL) at 4 C overnight. Crystals of the complex were grown, mixing an equal volume of the complex with the crystallization condition (100 mM Tris, pH 8.5, 100 mM Li2SO4, 20-24% PEG4000, 10 mM TCEP). Crystals were cryoprotected by a quick soak into the following cryosolution 100 mM Tris pH 8.5, 100 mM Li2SO4, 24% PEG4000, 10 mM TCEP, 35% ethylene glycol and then flash-frozen. Diffraction data were collected at synchrotron facilities in beamline ID30-1 at ESRF (Grenoble, France) (compounds 5, 7) or the XALOC beamline at ALBA (compound 6) and processed with XDS. 29 To provide an initial set of phases, the molecular replacement protocol in Phaser was used using the FAK kinase model from PDB 2JKK. 30 Refinement was carried out using the program Refmac and manual rebuilding was performed with Coot. [31] [32] 
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